Medication Adherence in Elderly — MCQs
Which of the following is NOT a component of DOTS?
Which of the following is a non- modifiable risk factor for CHD -
What is the most appropriate statistical test to test the statistical significance of the change in blood cholesterol levels after a month's treatment with atorvastatin?
A 55-year-old male, known smoker, complains of calf pain while walking. He experiences calf pain while walking but can continue walking with effort. Which grade of claudication does this patient fall under?
You are starting services for hypertension in your PHC. 50 patients who required antihypertensive treatment were transferred from another center. 40 of them were on amlodipine ( 5 mg PO) and 10 were on lisinopril ( 10 mg PO) as they had contraindications to the use of amlodipine. The drugs are supplied at the PHC on a monthly basis and you have to place an order for their medications. What is the number of tablets that you will order and the reorder factor?
A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
What is the effect of indomethacin on the ductus arteriosus?
Dosage of a drug in a child is typically calculated based on which of the following parameters?
What agent is used for pupil dilatation in children?
Which vitamin deficiency is most commonly seen in a pregnant mother receiving phenytoin therapy for epilepsy?
Medication Adherence in Elderly Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following is NOT a component of DOTS?
- A. Uninterrupted drug supply
- B. Accountability
- C. Political commitment
- D. Medicines given for 30 days (Correct Answer)
Explanation: ***Medicines given for 30 days*** - A core component of **DOTS (Directly Observed Treatment, Short-course)** is direct observation of medication intake, often on a daily or thrice-weekly basis, to ensure **adherence** and **treatment completion**. - Medications are dispensed in amounts for directly observed administration, typically **daily or thrice weekly**, not in 30-day supplies for unsupervised use. *Uninterrupted drug supply* - This is a crucial component of DOTS to ensure that patients receive their full course of treatment without interruptions. - An **uninterrupted supply** prevents drug resistance and treatment failure. *Accountability* - Accountability is integral to DOTS, ensuring that health workers and systems are responsible for patient follow-up and monitoring treatment outcomes. - This promotes thorough and **effective program implementation**. *Political commitment* - Strong political commitment from governments and health authorities is essential for the successful implementation and sustenance of DOTS programs. - This commitment ensures adequate **funding, resources, and policy support** for TB control efforts.
Question 2: Which of the following is a non- modifiable risk factor for CHD -
- A. Diabetes
- B. Smoking
- C. Hypertension
- D. Old age (Correct Answer)
Explanation: Old age - Age is a **non-modifiable risk factor** for Coronary Heart Disease (CHD) because it is an inherent biological process that cannot be changed [3]. - The risk of developing CHD **increases with age** due to cumulative exposure to other risk factors and natural wear and tear on the cardiovascular system [3]. *Diabetes* - Diabetes is a **modifiable risk factor** for CHD because it can be managed and controlled through lifestyle changes, medication, and regular monitoring [2]. - **Poorly controlled diabetes** significantly increases the risk of heart disease by damaging blood vessels and promoting atherosclerosis. *Smoking* - Smoking is a highly **modifiable risk factor** for CHD as it can be completely stopped [1], [2]. - **Cessation of smoking** significantly reduces the risk of heart attack and stroke over time [1]. *Hypertension* - Hypertension is a **modifiable risk factor** for CHD because blood pressure can be lowered through lifestyle interventions, such as diet and exercise, and pharmacotherapy [2]. - **Uncontrolled high blood pressure** places increased stress on the heart and blood vessels, accelerating the development of atherosclerosis [1].
Question 3: What is the most appropriate statistical test to test the statistical significance of the change in blood cholesterol levels after a month's treatment with atorvastatin?
- A. Paired t-test (Correct Answer)
- B. Unpaired or independent t-test
- C. Analysis of variance
- D. Chi-square test
Explanation: ***Paired t-test*** * A **paired t-test** is appropriate when comparing two means from the **same group of subjects** measured at two different time points (before and after treatment). * In this scenario, a single group's blood cholesterol levels are measured *before* and *after* atorvastatin treatment, making the observations dependent. *Unpaired or independent t-test* * An **unpaired t-test** is used to compare the means of two *independent* groups. * It would be used, for instance, if cholesterol levels were being compared between a group receiving atorvastatin and a separate control group. *Analysis of variance* * **Analysis of variance (ANOVA)** is used to compare **three or more means**. * It would be appropriate if there were multiple treatment groups or multiple time points for comparison beyond just two. *Chi-square test* * The **Chi-square test** is used to examine the association between **categorical variables**. * It would not be suitable here, as blood cholesterol level is a continuous numerical variable, not a categorical one.
Question 4: A 55-year-old male, known smoker, complains of calf pain while walking. He experiences calf pain while walking but can continue walking with effort. Which grade of claudication does this patient fall under?
- A. Grade I (Mild claudication)
- B. Grade II (Moderate claudication) (Correct Answer)
- C. Grade III (Severe claudication)
- D. Grade IV (Ischemic rest pain)
Explanation: ***Grade II (Moderate claudication)*** - **Grade II claudication** is characterized by **intermittent claudication** where the patient experiences pain while walking but can **continue walking with effort**. - This level of claudication reflects a moderate degree of peripheral arterial disease, where blood flow is sufficiently compromised to cause pain with exertion but not severe enough to force immediate cessation of activity. - The patient in this scenario can continue ambulation despite discomfort, which is the defining feature of this grade. *Grade I (Mild claudication)* - **Grade I claudication** involves discomfort or pain that the patient can **tolerate without significantly altering their gait or pace**. - In this stage, the pain is minimal, and the patient may perceive it as a dull ache or mild fatigue rather than true pain. - Walking can continue without significant effort or limitation. *Grade III (Severe claudication)* - **Grade III claudication** is marked by pain that is **severe enough to stop the patient from walking within a short distance** (typically less than 200 meters). - The pain forces the patient to rest and recover before they can resume walking. - This represents significant functional limitation in daily activities. *Grade IV (Ischemic rest pain)* - **Grade IV**, also known as **critical limb ischemia**, involves **pain even at rest**, especially in the feet or toes, often worsening at night when the limb is elevated. - This stage indicates severe arterial obstruction and is frequently associated with **ulcers, non-healing wounds, or gangrene**. - This represents advanced peripheral arterial disease requiring urgent intervention. **Note:** This grading system is a simplified clinical classification. The standard medical classifications for peripheral arterial disease are the **Fontaine classification** (Stages I-IV) and **Rutherford classification** (Categories 0-6).
Question 5: You are starting services for hypertension in your PHC. 50 patients who required antihypertensive treatment were transferred from another center. 40 of them were on amlodipine ( 5 mg PO) and 10 were on lisinopril ( 10 mg PO) as they had contraindications to the use of amlodipine. The drugs are supplied at the PHC on a monthly basis and you have to place an order for their medications. What is the number of tablets that you will order and the reorder factor?
- A. 1000, rf=3
- B. 1600, rf=2 (Correct Answer)
- C. 1200, rf=2
- D. 1400, rf=3
Explanation: ***1600, rf=2*** - **Monthly requirement calculation:** 40 patients need amlodipine (40 × 30 = 1,200 tablets/month) and 10 patients need lisinopril (10 × 30 = 300 tablets/month), totaling **1,500 tablets per month**. - With a **reorder factor of 2**, the inventory management principle suggests maintaining stock for potential delays. Using the formula: Order quantity = (Monthly need × Lead time) + Safety stock, this yields approximately **1,600 tablets** accounting for a practical buffer. - This represents a **rational inventory level** balancing supply continuity against storage constraints in a PHC setting. *1000, rf=3* - This quantity (1,000 tablets) is **insufficient** as it doesn't even cover one month's requirement of 1,500 tablets. - A reorder factor of 3 with inadequate base quantity would lead to **stockout** and treatment interruption. *1200, rf=2* - This covers only the **amlodipine requirement** (1,200 tablets) but completely omits the lisinopril requirement (300 tablets). - Would result in **immediate stockout** of lisinopril for 10 patients, compromising patient care. - Does not account for any **safety stock** or lead time buffer. *1400, rf=3* - While closer to the monthly need, **1,400 tablets is still below** the 1,500 required monthly. - A reorder factor of 3 is inconsistent with monthly ordering cycles and would suggest excessive inventory if properly calculated. - Does not follow standard **pharmaceutical inventory management** principles for this scenario.
Question 6: A drug is more likely to cause toxicity in elderly patients due to all of the following reasons except which of the following?
- A. decreased renal excretion of drugs
- B. decreased hepatic metabolism
- C. decreased volume of distribution (Correct Answer)
- D. increased receptor sensitivity
Explanation: ***decreased volume of distribution*** - A **decreased volume of distribution** would generally lead to a higher peak plasma concentration for a given dose, potentially increasing drug effect and thus toxicity, particularly for **hydrophilic drugs**. - However, for drugs that primarily distribute into **fat** or have a large volume of distribution, age-related changes in body composition (e.g., increased body fat, decreased total body water) can actually lead to an **increased volume of distribution** for some lipophilic drugs. *decreased renal excretion of drugs* - **Aging** is associated with a decline in **glomerular filtration rate (GFR)** and **renal tubular function**, leading to reduced drug clearance. - This results in a longer **half-life** and accumulation of renally excreted drugs, increasing the risk of **toxicity**. *decreased hepatic metabolism* - Liver size, blood flow, and the activity of some **cytochrome P450 enzymes** may decrease with age. - This leads to reduced **first-pass metabolism** and slower systemic clearance of many hepatically metabolized drugs, increasing their **bioavailability** and plasma concentrations. *increased receptor sensitivity* - Elderly patients often exhibit altered **pharmacodynamic responses**, including **increased sensitivity** to certain drugs. - This means a lower concentration of the drug at the receptor site can produce a greater therapeutic or toxic effect, making them more susceptible to **adverse drug reactions**.
Question 7: What is the effect of indomethacin on the ductus arteriosus?
- A. Closure of the ductus in premature neonates (Correct Answer)
- B. Patent ductus arteriosus
- C. Closure of the ductus in term and premature neonates
- D. Closure of the ductus in older children
Explanation: **Explanation:** **Mechanism of Action:** The patency of the ductus arteriosus (DA) in utero is maintained by high levels of circulating **Prostaglandin E2 (PGE2)**, which acts as a potent vasodilator. **Indomethacin** is a non-selective Cyclooxygenase (COX) inhibitor. By inhibiting the COX enzyme, it decreases the synthesis of PGE2, leading to the constriction and subsequent functional **closure of the ductus arteriosus.** **Why Option A is Correct:** Indomethacin is specifically effective in **premature neonates** because their ductal tissue is highly sensitive to prostaglandin levels. In these infants, the ductus often fails to close spontaneously due to hypoxia or immature lungs, and pharmacological intervention can prevent the need for surgical ligation. **Analysis of Incorrect Options:** * **Option B:** This describes the pathology itself. Indomethacin is the *treatment* for Patent Ductus Arteriosus (PDA), not the cause. * **Option C:** Indomethacin is generally **ineffective in term neonates**. In full-term infants, the ductal smooth muscle is more developed and less dependent on prostaglandins for patency; closure is primarily driven by the postnatal rise in oxygen tension. * **Option D:** In older children, the ductus has typically undergone anatomical remodeling (fibrosis into the ligamentum arteriosum) or is too structurally fixed for prostaglandin inhibition to have any effect. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** While Indomethacin was the traditional gold standard, **Ibuprofen (IV)** is now often preferred due to a lower risk of renal toxicity and necrotizing enterocolitis (NEC). * **Alternative:** **Paracetamol (Acetaminophen)** is an emerging alternative for PDA closure with a superior safety profile. * **Opposite Effect:** If a neonate has a cyanotic heart defect (e.g., Transposition of Great Arteries), we want to keep the ductus open. The drug used for this is **Alprostadil (PGE1 analog)**.
Question 8: Dosage of a drug in a child is typically calculated based on which of the following parameters?
- A. Race
- B. Weight (Correct Answer)
- C. Sex
- D. Height
Explanation: **Explanation:** In pediatric pharmacology, drug dosing is not a "one size fits all" approach because children are not merely "small adults." Their physiological processes—including gastric emptying, total body water percentage, and organ maturation—differ significantly. **Why Weight is the Correct Answer:** Body weight (expressed in mg/kg) is the most common and practical parameter used for calculating pediatric dosages. It accounts for the significant variations in size across different pediatric age groups (neonates to adolescents). While **Body Surface Area (BSA)** is technically the most accurate method for drugs with a narrow therapeutic index (like chemotherapy), **weight-based dosing** remains the standard clinical gold standard for most routine medications due to its ease of calculation and reliability. **Why Other Options are Incorrect:** * **Race (A):** While pharmacogenomics can influence drug metabolism (e.g., Isoniazid acetylation), race is never used as a primary parameter for calculating initial pediatric dosages. * **Sex (C):** Hormonal differences between sexes generally do not impact drug dosing until puberty; it is not a standard parameter for pediatric calculations. * **Height (D):** Height alone does not account for body mass or metabolic capacity. It is, however, used as a component to calculate BSA. **High-Yield Clinical Pearls for NEET-PG:** * **Young’s Formula:** $Age / (Age + 12) \times \text{Adult Dose}$ (Used for children > 2 years). * **Dilling’s Formula:** $Age / 20 \times \text{Adult Dose}$ (Easier to calculate, often tested). * **Fried’s Formula:** $Age (\text{in months}) / 150 \times \text{Adult Dose}$ (Used specifically for infants). * **Clark’s Rule:** $Weight (\text{in lbs}) / 150 \times \text{Adult Dose}$ (Based on weight). * **Gold Standard:** BSA-based dosing is superior to weight-based dosing for precision but is more complex to calculate ($BSA = \sqrt{[Height(cm) \times Weight(kg)] / 3600}$).
Question 9: What agent is used for pupil dilatation in children?
- A. Atropine (Correct Answer)
- B. Homatropine
- C. Tropicamide
- D. Phenylephrine
Explanation: **Explanation:** In pediatric ophthalmology, the drug of choice for pupil dilatation and cycloplegic refraction is **Atropine**. **1. Why Atropine is Correct:** Children have very high accommodative power due to a strong ciliary muscle. To perform an accurate refraction (especially to detect latent hypermetropia or accommodative esotropia), complete paralysis of the ciliary muscle (**cycloplegia**) is required. Atropine is the most potent cycloplegic available. It is typically administered as a 1% ointment or drops for 3 days prior to the examination to ensure maximal effect. **2. Why the other options are incorrect:** * **Homatropine:** It is a semi-synthetic derivative of atropine but is significantly less potent. It is rarely used for refraction in children because it may result in incomplete cycloplegia. * **Tropicamide:** While it has the fastest onset and shortest duration (making it the drug of choice for adults), its cycloplegic action is too weak for the strong accommodative reflex of a child. * **Phenylephrine:** This is a sympathomimetic (alpha-1 agonist) that causes mydriasis (dilation) but **no cycloplegia**. It is often used as an adjunct but cannot be used alone for pediatric refraction. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Atropine is the DOC for children <7 years; Cyclopentolate is preferred for children 7–12 years; Tropicamide is preferred for adults. * **Systemic Toxicity:** In children, always apply pressure over the lacrimal sac (punctal occlusion) after instilling drops to prevent systemic absorption, which can cause "Atropine flushing," fever, and tachycardia. * **Contraindication:** Avoid atropine in children with Down Syndrome, as they may show an exaggerated pupillary response and heart rate.
Question 10: Which vitamin deficiency is most commonly seen in a pregnant mother receiving phenytoin therapy for epilepsy?
- A. Vitamin B6
- B. Vitamin B12
- C. Vitamin A
- D. Folic acid (Correct Answer)
Explanation: **Explanation:** **Phenytoin** is a widely used antiepileptic drug known for its specific metabolic side effects, particularly regarding folate metabolism. **Why Folic Acid is the Correct Answer:** Phenytoin causes folic acid deficiency through three primary mechanisms: 1. **Inhibition of Absorption:** It inhibits the enzyme intestinal conjugase, which is required to break down dietary polyglutamates into absorbable monoglutamates. 2. **Enzyme Induction:** As a potent inducer of hepatic CYP450 enzymes, phenytoin increases the demand for folate as a co-factor in drug metabolism. 3. **Antagonism:** It may interfere with the uptake of folate by cells. In pregnant women, this deficiency is critical as it significantly increases the risk of **Neural Tube Defects (NTDs)** and can lead to megaloblastic anemia. **Why Other Options are Incorrect:** * **Vitamin B6 (Pyridoxine):** Deficiency is classically associated with **Isoniazid (INH)** therapy, not phenytoin. * **Vitamin B12:** While B12 deficiency also causes megaloblastic anemia, phenytoin specifically targets folate pathways. B12 deficiency is more common in metformin use or gastric bypass. * **Vitamin A:** Phenytoin does not interfere with the absorption or metabolism of fat-soluble Vitamin A. **High-Yield Clinical Pearls for NEET-PG:** * **Fetal Hydantoin Syndrome:** Characterized by craniofacial anomalies (cleft lip/palate), microcephaly, and hypoplastic phalanges/nails. * **Vitamin K Deficiency:** Phenytoin can also cause a deficiency of Vitamin K in the newborn, leading to coagulation defects. Prophylactic Vitamin K is often given to the mother in the last month of pregnancy. * **Management:** Pregnant women on phenytoin should receive high-dose folic acid (5 mg/day) to mitigate the risk of NTDs.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free